Epidemiology reports helps to understand the prevalence and incidence data of chosen indication by geography through methodical research using various sources. FirstView Insight’s epidemiology reports, by focusing on prevalence and incidence data helps to understand the severity of the disease, and its characterization in terms of age, sex and subtypes to report epidemiological information. This report helps in evaluating the size of the overall addressable market and how market dynamics may change according to disease epidemiology.
Portfolio management for pharma industry is incomparable with any other business sector owing to extremely high financial risks and failure rates and large investments. The costs for Research and development in a single pharma company with multiple products may run into the hundreds of millions of dollars. The failure rates for are also very high. With a company’s success depending entirely on the decisions regarding which products to support and which to deprioritize, choosing the right portfolio management service is as crucial a choice as selecting which specific product development program to fund. Investment in portfolio management indicates towards a shift in pharma’s resource allocation towards bringing about better operational and capital efficiency.
Epidemiology reports helps to understand the prevalence and incidence data of chosen indication by geography through methodical research using various sources. FirstView Insight’s epidemiology reports, by focusing on prevalence and incidence data helps to understand the severity of the disease, and its characterization in terms of age, sex and subtypes to report epidemiological information. This report helps in evaluating the size of the overall addressable market and how market dynamics may change according to disease epidemiology.
We design specific solutions that would aid your company to develop efficient strategies to achieve optimum risk/return profile. By leveraging on the robust data analysis, we can predict and quantify the probability of approval and success rate for any particular molecule.
Based on our in-depth research we provide actionable insights for our clients to help them to identify and evaluate the viable business opportunities to accelerate organizational growth. Our evaluation is based on benchmarking other relevant transactions in the space, and comparing deal structures and financial payment mechanisms. We provide support in keeping our customers well informed about the disease and market landscape, unmet needs and the best opportunities available for in-licensing, out-licensing or acquisition. We also cover the recent pharma trends and their implications for the business strategies.
Benchmarking is crucial for business success as it allows comparison between the performance characteristics of competitor organizations aimed at enabling each participant to improve its performance in the marketplace. It helps to obtain clear understanding of competitors and of customers' requirements. It also enables rapid adoption of innovative practices throughout industry. We believe in providing end-to-end support for a company determined to improve its performance with learnings from other players in industry.